MedTrace Logo

Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration

NCT03338335 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 16000

Last updated 2018-02-22

No results posted yet for this study

Summary

this study is an individual patient level meta-analysis of randomized clinical trials, to evaluate the influence of ethnicity, to study whether the relative tradeoff between ischemia and bleeding is distinct by ethnicity.

Conditions

Interventions

DRUG

prolonged DAPT

Dual antiplatelet therapy will be prescribed for more than 12 months

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Eligibility

Min Age
19 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-01
Primary Completion
2018-03-31
Completion
2018-10-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03338335 on ClinicalTrials.gov